SYNAIRGEN PLC — Share Issue/Capital Change 2013

Oct 14, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4126Q

Synairgen plc

14 October 2013

Synairgen plc

('Synairgen' or the 'Company')

Exercise of Options

Southampton, UK - 14 October 2013: Synairgen plc (LSE: SNG), the respiratory drug development company developing inhaled IFN-beta as a broad spectrum antiviral for asthma, COPD and severe viral lung infections, announces that it has applied for 11,555 ordinary shares of one pence each (the 'Option Shares') to be admitted to trading on the AIM Market of the London Stock Exchange ('AIM') ('Admission'). It is expected that Admission will occur and that dealings will commence in the Option Shares on 17 October 2013.

The Options Shares are being issued pursuant to the exercise of options by certain former employees of the Company. The Options Shares will rank pari passu with the Company's existing ordinary shares.

Following Admission, the number of Ordinary Shares in issue and admitted to trading on AIM will be 75,195,891.

- Ends -

For further information, call

Synairgen plc Richard Marsden, CEO John Ward, Finance Director	+44 (0)23 8051 2800
finnCap Ltd Geoff Nash  Christopher Raggett	+44 (0)20 7220 0500
Newgate Threadneedle  Graham Herring  Josh Royston	+44 (0)20 7653 9850

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCNKQDPOBDKFKD